特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
251540

チクングニヤ熱:パイプライン製品の分析

Chikungunya Fever - Pipeline Review, H1 2020

出版日: | 発行: Global Markets Direct | ページ情報: 英文 126 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.84円
チクングニヤ熱:パイプライン製品の分析
出版日: 2020年04月30日
発行: Global Markets Direct
ページ情報: 英文 126 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

チクングニヤ熱は、ネッタイシマカに噛まれることでヒトにも伝染するウイルス性疾患の一種です。病原体であるチクングニヤウイルス(CHIKV)はトガウイルス科アルファウイルス属に属しています。主な症状として、消耗性の関節痛や、関節部の腫脹・硬直化、筋肉痛、頭痛、倦怠感、吐き気・嘔吐、発疹・発熱などが挙げられます。非ステロイド系抗炎症性薬物(NSAID)などが主な治療薬となっています。

当レポートでは、世界各国でのチクングニヤ熱治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

チクングニヤ熱の概要

治療薬の開発

  • チクングニヤ熱向けパイプライン製品:概要
  • 企業別のパイプライン製品
  • 大学/研究機関別のパイプライン製品
  • チクングニヤ熱治療薬:開発中の製品の一覧(企業別)
  • チクングニヤ熱治療薬:研究中の製品の一覧(大学/研究機関別)

チクングニヤ熱:治療薬の評価

  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

チクングニヤ熱治療薬の開発に従事している企業

  • Abivax SA
  • Arbovax Inc
  • Arno Therapeutics Inc
  • Bharat Biotech International Ltd
  • Ennaid Therapeutics LLC
  • Etubics Corp
  • Griffith University
  • Hawaii Biotech Inc
  • Indian Immunologicals Ltd
  • Inovio Pharmaceuticals Inc
  • Integral Molecular Inc
  • Integrated BioTherapeutics Inc
  • Merck & Co Inc
  • Mymetics Corp
  • Nanotherapeutics Inc
  • PaxVax Inc
  • Profectus BioSciences Inc
  • Shionogi & Co Ltd
  • 武田薬品工業
  • Themis Bioscience GmbH
  • Theravectys SA
  • Valneva SE
  • Vaxart Inc

薬剤のプロファイル

チクングニヤ熱治療薬:開発が休止状態の製品

チクングニヤ熱関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

図表

List of Tables

  • Number of Products under Development for Chikungunya Fever, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Chikungunya Fever - Pipeline by Activirosomes Ltd, H1 2020
  • Chikungunya Fever - Pipeline by Bharat Biotech Ltd, H1 2020
  • Chikungunya Fever - Pipeline by Bow Therapeutics, H1 2020
  • Chikungunya Fever - Pipeline by Ciloa, H1 2020
  • Chikungunya Fever - Pipeline by Clayton Biotechnologies Inc, H1 2020
  • Chikungunya Fever - Pipeline by Emergent BioSolutions Inc, H1 2020
  • Chikungunya Fever - Pipeline by Emergex Vaccines Ltd, H1 2020
  • Chikungunya Fever - Pipeline by Ennaid Therapeutics LLC, H1 2020
  • Chikungunya Fever - Pipeline by Etubics Corp, H1 2020
  • Chikungunya Fever - Pipeline by Hawaii Biotech Inc, H1 2020
  • Chikungunya Fever - Pipeline by HSRx Group, H1 2020
  • Chikungunya Fever - Pipeline by Immunomodulation Inc, H1 2020
  • Chikungunya Fever - Pipeline by Imophoron Ltd, H1 2020
  • Chikungunya Fever - Pipeline by Indian Immunologicals Ltd, H1 2020
  • Chikungunya Fever - Pipeline by Inovio Pharmaceuticals Inc, H1 2020
  • Chikungunya Fever - Pipeline by Integral Molecular Inc, H1 2020
  • Chikungunya Fever - Pipeline by Integrated BioTherapeutics Inc, H1 2020
  • Chikungunya Fever - Pipeline by Medigen Inc, H1 2020
  • Chikungunya Fever - Pipeline by Moderna Inc, H1 2020
  • Chikungunya Fever - Pipeline by Najit Technologies Inc, H1 2020
  • Chikungunya Fever - Pipeline by Pai Life Sciences Inc, H1 2020
  • Chikungunya Fever - Pipeline by Paradigm Biopharmaceuticals Ltd, H1 2020
  • Chikungunya Fever - Pipeline by Precision Virologics Inc, H1 2020
  • Chikungunya Fever - Pipeline by Profectus BioSciences Inc, H1 2020
  • Chikungunya Fever - Pipeline by ProtInhi BV, H1 2020
  • Chikungunya Fever - Pipeline by Riboscience LLC, H1 2020
  • Chikungunya Fever - Pipeline by Ridgeback Biotherapeutics LP, H1 2020
  • Chikungunya Fever - Pipeline by Sementis Ltd, H1 2020
  • Chikungunya Fever - Pipeline by Shionogi & Co Ltd, H1 2020
  • Chikungunya Fever - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
  • Chikungunya Fever - Pipeline by Themis Bioscience GmbH, H1 2020
  • Chikungunya Fever - Pipeline by Valneva SE, H1 2020
  • Chikungunya Fever - Pipeline by Vaxart Inc, H1 2020
  • Chikungunya Fever - Pipeline by VenatoRx Pharmaceuticals Inc, H1 2020
  • Chikungunya Fever - Dormant Projects, H1 2020
  • Chikungunya Fever - Dormant Projects, H1 2020 (Contd..1), H1 2020

List of Figures

  • Number of Products under Development for Chikungunya Fever, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
目次
Product Code: GMDHC12150IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chikungunya Fever - Pipeline Review, H1 2020, provides an overview of the Chikungunya Fever (Infectious Disease) pipeline landscape.

Chikungunya is a viral disease transmitted to humans by the bite of infected Aedes aegypti mosquitoes. Chikungunya virus (CHIKV) is a member of the genus Alpha virus, in the family Togaviridae. Symptoms of Chikungunya includes debilitating arthralgia (joint pain), swelling of joints, stiffness of joints, myalgia (muscular pain), headache, fatigue (weakness), nausea, vomiting and rash and fever. Treatment includes use of NSAIDs.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chikungunya Fever - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Chikungunya Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chikungunya Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chikungunya Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 4, 22 and 8 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 7 and 2 molecules, respectively.

Chikungunya Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chikungunya Fever (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Chikungunya Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chikungunya Fever (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chikungunya Fever (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chikungunya Fever (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chikungunya Fever (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chikungunya Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Chikungunya Fever - Overview
  • Chikungunya Fever - Therapeutics Development
  • Chikungunya Fever - Therapeutics Assessment
  • Chikungunya Fever - Companies Involved in Therapeutics Development
  • Chikungunya Fever - Drug Profiles
  • Chikungunya Fever - Dormant Projects
  • Chikungunya Fever - Product Development Milestones
  • Appendix
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.